Magrolimab will no longer be in development as a treatment option for patients with hematologic malignancies.
Sabrina Serani
Sabrina Serani is the assistant managing editor for Targeted Oncology.
Articles by Sabrina Serani
Along with the FDA, the European Medicines Agency has also accepted the application of nivolumab and chemotherapy in operable non–small cell lung cancer.
Combining olaptesed pegol with bevacizumab and radiotherapy showed a 10-fold improvement in survival rate compared with the standard-of-care among patients with glioblastoma.
The FDA’s Oncologic Drug Advisory Committee will be held on March 15, 2024, to review data pertaining to the supplemental biologics license application of ide-cel in relapsed or refractory multiple myeloma.
In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.
In an interview with Targeted Oncology, Sanjay Goel, MD, MS, discussed the mystery of cachexia in pancreatic cancer and why it remains a challenging symptom to target.
Rates of enrollment in clinical trials were notably lower among Asian, Black, and Hispanic patients with gynecologic cancers compared with White women.
In an interview with Targeted Oncology, Stephen Williams, MD, discussed a retrospective cohort study presented at ASCO GU analyzing intravesical gemcitabine usage vs Bacillus Calmette-Guérin for the treatment of high-risk non-muscle invasive bladder cancer.
In an interview with Targeted Oncology, Guenther Koehne, MD, discussed the latest research surrounding autologous and allogeneic stem cell transplants.
The application is based on promising findings from the phase 3 PERSEUS trial which were presented at the American Society of Hematology Annual Meeting in December 2023.
The FDA and Japan’s Ministry of Health, Labor, and Welfare advanced lisocabtagene maraleucel for relapsed/refractory follicular and mantle cell lymphomas.
Research across kidney, bladder, and prostate cancers was showcased January 25-27 in San Francisco, California.
If approved, trastuzumab deruxtecan would be the first HER2-directed antibody-drug conjugate for a tumor-agnostic indication.
In an interview with Targeted Oncology, Mark Dybul, MD, discussed a breakthrough method of immunotherapy in solid tumors.
The combination of pembrolizumab and lenvatinib appears to be effective in for the treatment of patients with endometrial cancer, regardless of biomarker status.
The phase 3 ASCERTAIN study found that orally administered decitabine and cedazuridine had similar pharmacologic effects compared with intravenously administered decitabine.
Tamoxifen, a selective estrogen receptor modulator, shows potential as a line of treatment in some patients with myeloproliferative neoplasms.
Patients with extensive-stage small cell lung cancer experienced longer rates of survival when treated with atezolizumab induction and maintenance therapy vs placebo.
The FDA has accepted the biologics license application for obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
In an interview with Targeted Oncology, Guenther Koehne, MD, provides a comprehensive overview of the dynamic landscape and evolving strategies in immunotherapy for hematologic malignancies.
The phase 3 EVOKE-01 trial of sacituzumab govitecan in non–small cell lung cancer missed its primary end point, showing a numerical but not significant improvement in overall survival.
Findings from the phase 2 CAPTIVATE study demonstrate that the doublet of ibrutinib and venetoclax may be an attractive line of therapy for patients with chronic lymphocytic leukemia.
In an interview with Targeted Oncology, Louise Morrell, MD, discussed the landscape of genetic testing in oncology and the latest advancements in the field.
Using ctDNA to detect minimal residual disease in patients with stage II/III colorectal cancer appeared to show strong prognosis of disease recurrence and benefit to adjuvant chemotherapy.
The FDA has approved erdafitinib for the treatment of locally advanced or metastatic urothelial carcinoma with FGFR3 alterations.
The tumor treating fields device has been given premarket approval in combination with standard therapies for the treatment of platinum-resistant non–small cell lung cancer.
In an interview with Targeted Oncology, Naomi Dempsey, MD, provided insight into the benefits of endocrine therapy in patients with breast cancer and the implications of findings from this research.
The DermaSensor device is a noninvasive tool that can diagnose skin cancer, including the 3 most common types, right at the point of testing.
Findings from a phase 2 study found that treatment with axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma led to a complete metabolic response of 71%.
Positive findings from the KEYNOTE-A18 trial support the approval of pembrolizumab, radiotherapy, and concurrent chemotherapy in patients with high-risk locally advanced cervical cancer.